Skip to main content
Premium Trial:

Request an Annual Quote

Leonardo Receives $2.5M Grant from Texas Technology-Development Fund


Arrowhead Research this week said that its subsidiary Leonardo Biosystems has received a $2.5 million grant from the Texas Emerging Technology Fund to support the company's development of a proprietary drug-delivery system.

Leonardo, which had been expecting the funding, intends to use the money to ramp up its operations with the goal of securing industry partnerships around its so-called multi-stage delivery approach (GSN 5/27/2010).

The technology involves multi-stage system comprising mesoporous silicon particles containing neutral nanoliposomes carrying a drug payload.

In May, Leonardo Co-founder and University of Texas Health Science Center researcher Mauro Ferrari reported in Cancer Research how the system was able to deliver siRNAs targeting the oncoprotein EphA2 into two mouse models of ovarian cancer.

“Leonardo’s proprietary nanoparticle delivery system is designed to overcome the body’s natural defense mechanisms, which make it difficult or impossible to effectively deliver many promising therapeutics, especially in cancer," Leonardo CEO Bruce Given said in a statement. "This award from the ETF allows us to keep this crucial technology in Texas, where we hope to develop it to its full potential.”

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.